Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496), has announced the publication of clinical trial results for its dual-target bispecific antibody drug M701, which targets Ep CAM and CD3, in the treatment of malignant ascites caused by advanced epithelial tumors. This recognition in an internationally renowned medical journal signifies the clinical value of the innovative therapy [1]. Group I: Clinical Trial Results - The Phase II study aimed to evaluate the efficacy and safety of M701 administered via intraperitoneal infusion in patients with moderate to severe malignant ascites due to advanced epithelial tumors. A total of 84 patients were enrolled, with 43 assigned to the M701 group receiving intraperitoneal infusion after paracentesis [1]. - The median puncture-free survival time for the M701 group was 75 days, compared to 25 days for the control group, showing a significant difference (p=0.0065) [1]. - Subgroup analysis indicated that various cancer types, including gastric, colorectal, and ovarian cancers, benefited from M701 infusion. Patients with a baseline relative lymphocyte count of ≥13% exhibited better efficacy [1]. Group II: Survival Rates - The overall survival time for patients in the M701 group was extended compared to the control group. The six-month survival rates were 33.3% for the M701 group and 12.1% for the control group [1]. - No other serious adverse events were observed in the M701 group, indicating a favorable safety profile for the treatment [1].
友芝友生物-B于《实验血液学与肿瘤学》上发表M 701恶性腹水II期数据